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Abstract
Background: Leprosy Type 1 reactions are a major cause of nerve damage and the preventable disability that results. Type 1
reactions are treated with oral corticosteroids and there are few data to support the optimal dose and duration of
treatment. Type 1 reactions have a Th1 immune profile: cells in cutaneous and neural lesions expressing interferon-c and
interleukin-12. Methylprednisolone has been used in other Th1 mediated diseases such as rheumatoid arthritis in an
attempt to switch off the immune response and so we investigated the efficacy of three days of high dose (1 g) intravenous
methylprednisolone at the start of prednisolone therapy in leprosy Type 1 reactions and nerve function impairment.
Results: Forty-two individuals were randomised to receive methylprednisolone followed by oral prednisolone (n = 20) or
oral prednisolone alone (n = 22). There were no significant differences in the rate of adverse events or clinical improvement
at the completion of the study. However individuals treated with methylprednisolone were less likely than those treated
with prednisolone alone to experience deterioration in sensory function between day 29 and day 113 of the study. The
study also demonstrated that 50% of individuals with Type 1 reactions and/or nerve function impairment required
additional prednisolone despite treatment with 16 weeks of corticosteroids.
Conclusions: The study lends further support to the use of more prolonged courses of corticosteroid to treat Type 1
reactions and the investigation of risk factors for the recurrence of Type 1 reaction and nerve function impairment during
and after a corticosteroid treatment.
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Introduction
Leprosy is a chronic granulomatous infection principally
affecting the skin and peripheral nerves caused by the obligate
intracellular organism Mycobacterium leprae [2]. The disease causes
skin lesions and neuropathy. Complications secondary to the
neuropathy can result in deformity and disability. 249 007 new
cases of leprosy were diagnosed and reported to World Health
Organization (WHO) in 2008 [3].
Type 1 reactions (T1Rs) are a major cause of nerve function
impairment (NFI) in patients with leprosy and affect up to 30% of
susceptible individuals [4]. T1Rs predominantly affect borderline
leprosy[4]. They may be a presenting feature of leprosy or occur
during multi-drug therapy (MDT) or after completion. A T1R is
characterised by acute inflammation in skin lesions or nerves or
both. Skin lesions become acutely inflamed and oedematous and
may ulcerate. Oedema of the hands, feet and face can also be a
feature of a T1R.
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Leprosy T1Rs are treated with oral corticosteroids. However
treatment with a standardised reducing 12 week course of oral
prednisolone (total dose 1.68 g) which had been used in a previous
pilot study in Nepal resulted in 37% of individuals requiring
additional prednisolone [5]. The randomised controlled treatment
trials TRIPOD 2 and TRIPOD 3 that were reported during the
design of this study had both used a 16 week course of oral
prednisolone (total dose 2.52 g) [6,7].
T1Rs appear to be mediated via Th1 type cells and lesions in
reaction express the pro-inflammatory IFNc, IL12 and the oxygen
free radical producer iNOS [8]. The expression of TNFa protein
in the skin and nerves of patients during T1Rs is increased[9].
High dose intravenous (IV) methylprednisolone (MP) has been
used as a standard treatment in the early phase of an exacerbation
of Th1 cytokine mediated relapsing chronic diseases. These
conditions include rheumatoid arthritis (RA) [10] and multiple
sclerosis (MS) [11]. In 18 patients with MS treated with IV MP 1 g
for three days there was a significant suppression of mitogen
stimulated IFNc, TNFa and IL2 production by blood leucocytes
ex vivo after treatment [12]. MP has also been shown to reduce
serum levels of TNFa in RA [13]. Eleven patients given 1 g IV
showed significantly reduced serum levels of TNFa at 4 and
24 hours. In a comparative study of lymphocyte-suppressive
potency between prednisolone and MP in 44 individuals with
RA the latter was more effective in those with greater disease
activity as defined by rheumatoid factor titres [14].
We compared three daily infusions of IV high dose MP and oral
prednisolone with a 16 week course of oral prednisolone alone.
High dose IV MP had not been used previously in a trial of
treatment of leprosy T1R so a Phase 2 trial was needed to confirm
safety before considering whether to proceed to a larger Phase 3
trial of clinical efficacy.
The aims of the trial were as follows:
1. To assess the safety and tolerability of high dose MP when
given to patients with leprosy T1Rs and patients with leprosy
associated acute neuritis with nerve function impairment in
Nepal.
2. To assess the effect of high dose MP on the clinical outcome of
leprosy T1Rs and leprosy associated acute neuritis with nerve
function impairment.
Methods
A double blind parallel-group randomised controlled trial was
designed to compare the safety and effect of early high dose IV
MP followed by oral prednisolone with IV Normal saline and oral
prednisolone. The study was approved by the Nepal Health
Research Council and the Ethics Committee of the London
School of Hygiene and Tropical Medicine (Number 4022).
Participants (aged between 16–65 years and weighing more
than 30 kg) were recruited from the leprosy service of Anandaban
Hospital, Kathmandu, Nepal. Two groups of individuals were
eligible for entry into the trial:
1. Individuals diagnosed as having leprosy with clinical evidence
of T1R of less than six months duration.
2. Individuals diagnosed with leprosy with new (less than six
months duration) NFI without inflammation of skin lesions (if
skin lesions were present).
Participants with any type of leprosy of the Ridley-Jopling
Classification [15] were eligible. Initially, enrolment into the study
required individuals with clinical evidence of a T1R to have
associated nerve function impairment. This was changed nine
months after the start of the trial so that individuals with T1Rs
involving the skin only would also be eligible for enrolment. This
was done because only 14 individuals had been recruited in this
period and recruitment had been optimal as determined by case
note review of a random selection of clinic attendees. The change
to this eligibility criterion was approved by the two Ethics
committees.
The following individuals were excluded: those unwilling to give
consent or return for follow-up or who had taken systemic steroids
within three months of enrolment, those who had received other
immunosuppressant therapy including thalidomide within three
months of enrolment, those with severe active infection such as
tuberculosis or severe intercurrent disease, those with a contrain-
dication to high dose methylprednisolone such as peptic ulcer
disease, diabetes mellitus, glaucoma and uncontrolled hyperten-
sion or known allergy to methylprednisolone. Pregnant women
were excluded and females of child bearing capacity were not
recruited unless they had at least one month of adequate
contraception.
The participants were treated with corticosteroids for 112 days.
The total duration of the study was 337 days from entry into the
trial. The intervention for the MP treated individuals was 1 gram
MP in Normal saline given as an IV infusion and eight dummy
tablets (Comprehensive Medical Services India, Chennai India)
identical in appearance to prednisolone tablets daily for the first
three days of the trial. The prednisolone treated individuals
received 40 mg (eight tablets) of prednisolone and an identical
appearing IV infusion which contained only Normal saline daily
Author Summary
Leprosy is caused by a bacterium and is curable with a
combination of antibiotics known as multi-drug therapy
that patients take for six or 12 months. However, a
significant proportion of leprosy patients experience
inflammation in their skin and/or nerves, which may occur
even after successful completion of multi-drug therapy.
These episodes of inflammation are called leprosy Type 1
reactions. Type 1 reactions are an important complication
of leprosy because they may result in nerve damage that
leads to disability and deformity. Type 1 reactions require
treatment with immunosuppressive agents such as corti-
costeroids. The optimum dose and duration of corticoste-
roid therapy remains unclear. We conducted a study to see
if it would be safe to use a large dose of a corticosteroid
called methylprednisolone for three days at the start of a
16 week corticosteroid treatment regime of prednisolone
in patients with leprosy Type 1 reactions and leprosy
patients with nerve damage present for less than six
months. We did this by comparing individuals who were
given methylprednisolone followed by prednisolone and
those who received just prednisolone. In this small study
we did not see any significant difference in the frequency
of adverse events due to corticosteroid treatment in the
two groups. We did not demonstrate a significant
difference in improvement in individuals in the methyl-
prednisolone group (who received a larger dose of
corticosteroids) than those in the prednisolone treated
group. Overall, approximately 50% of individuals required
more prednisolone in addition to the 16 week course of
treatment to prevent further nerve damage or reactions.
This suggests that it would be worthwhile to investigate
longer treatment courses with corticosteroids and other
immunosuppressive drugs.
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for the first three days of the trial. Thereafter individuals in both
groups received the same reducing course of prednisolone. This
course was prednisolone 40 mg daily from day 4 to day 14 of the
study. The amount of prednisolone was then reduced to 35 mg
daily for the next 14 days and then by a further 5 mg daily every
14 days to zero. An individual allocated to the MP group received
a total dose of corticosteroid equivalent to 6.15 g of prednisolone.
Individuals in the prednisolone alone group received 2.52 g of
prednisolone in total.
All individuals enrolled into the study received albendazole
400 mg daily for the first three days of the trial and famotidine
40 mg daily whilst they were receiving corticosteroids. The
albendazole was given to reduce the risk of hyperinfection with
Strongyloides stercoralis. The famotidine was used to reduce the risk of
peptic ulceration.
The primary outcome measure was the frequency of adverse
events in the two treatment arms. These were assessed by a study
physician prior to treatment and then at day 4 (after the three IV
infusions) and then days 8, 15, 29, 57, 85, 113, 141, 169, 197, 225,
253, 281, 309 and 337. Adverse events were enquired about and
examined for at each assessment. A standardized form contained a
list of adverse events attributable to corticosteroids which
participants were asked if they had experienced. There was also
a free text space available where other symptoms mentioned by
the study participants or identified by the physician could be
recorded. Adverse events were defined as major or minor in
accordance with the classification used in the TRIPOD studies
[16]. Major adverse events were defined as psychosis, peptic ulcer,
glaucoma, cataract, diabetes mellitus, severe infections (including
tuberculosis), infected neuropathic ulcers, hypertension and death.
Minor adverse events were defined as moon face, dermatophyte
fungal or yeast infections, acne and gastric pain requiring an
antacid (in addition to the famotidine each individual was
prescribed whilst on corticosteroids). Individuals were questioned
about the symptoms of nocturia, polyuria and polydipsia as a
method of screening for diabetes mellitus in addition to urinalysis
being performed.
Secondary outcomes measures were:
N change in the clinical severity score derived from the validated
Clinical Severity Scale [17] at days 4, 29, 113 and 337. The
Clinical Severity Scale uses a composite score of skin signs and
oedema, sensory and motor nerve function[17]. We had
previously developed the scale and demonstrated that it has a
Cronbach’s alpha of .0.8 and an Intra-Class Correlation
coefficient of 0.994.
N change in clinical nerve function impairment determined using
the validated Clinical Severity Scale at days 4, 29, 113 and
337.
N time to the next steroid requiring reactional episode or acute
nerve function impairment.
N the amount of supplementary prednisolone required in
addition to the reducing 16 week regimen.
Peripheral nerve function was assessed clinically. Sensory testing
(ST) was performed using two Semmes-Weinstein monofilaments
(SWM) (Sorri-Bauru, Bauru, Sa˜o Paulo, Brazil) at designated test
sites on the hands and feet as previously reported [17]. The
sensation in the areas of skin supplied by the ulnar and median
nerves was tested with 2 g and 10 g monofilaments. The area of
skin supplied by the posterior tibial nerve was tested with the 10 g
and 300 g monofilaments. Trigeminal nerve sensation was tested
using cotton wool. Voluntary muscle testing (VMT) was assessed
using the modified Medical Research Council grading of power
[18]. The facial nerve was tested by assessing forced eye closure.
The median nerve was tested using resisted thumb abduction, the
ulnar nerve by resisted little finger abduction and the radial nerve
by resisted wrist extension. The lateral popliteal nerve was tested
by resisted foot dorsiflexion. ST and VMT assessments were
carried out by trained physio-technicians and if necessary repeated
by the study physicians.
Patients with deterioration in nerve function or skin signs were
treated with further prednisolone. This was defined as a sustained
deterioration (for a period of at least two weeks) of nerve function,
the development of nerve pain unresponsive to analgesics,
palpable swelling of skin patches or new erythematous and raised
skin patches. Any decline in nerve function which the study
doctors believed required immediate additional prednisolone was
also regarded as deterioration. Individuals who experienced
deterioration in skin and/or nerve function whilst receiving a
dose of prednisolone less than 20 mg daily had the dose increased
back to 20 mg and reduced by 5 mg every 14 days to zero. The
exception to this was if they had a T1R involving a facial patch in
which case the prednisolone was increased to 40 mg regardless of
the dose of prednisolone the individual was taking. Individuals
taking a dose of prednisolone greater than 20 mg had their dose
increased to 40 mg and tapered by 5 mg every 14 days to zero.
In order to have 80% power to show that MP was not
associated with a significantly greater (a,0.05) rate of major
adverse effects it was calculated that the study would need 201
participants in each group based on a higher rate of 7%. Using this
same assumption but with the TRIPOD data for all the Nepali
participants (major adverse effect rate of 2.4%) then 64 individuals
would be needed to be enrolled in each arm.
Eligible individuals were enrolled consecutively. Block rando-
misation in groups of four using a table of random numbers
generated by Dr Peter Nicholls was used. A standard envelope
system was used for allocation concealment. The envelopes were
pre-packed in London by Dr Claire Watson who had no other
involvement with the study. The participants were randomly
allocated to the MP/prednisolone or the prednisolone alone arm
and so had an equal chance of being in either arm of the study.
The allocation procedure was decentralized and operated solely by
the chief pharmacist at Anandaban Hospital who kept a separate
record of the allocation. The pharmacist had no contact with the
study participants during their inpatient stay.
All study participants, physicians, ward staff and other assessors
(physio-technicians) were blinded to the allocation. Only Dr Peter
Nicholls had access to the study data and the randomisation code.
The allocation code was revealed to the other researchers once
recruitment, follow-up and data collection had been completed.
The data were stored in an Access database and analysed using
the Statistical Package for the Social Sciences (SPSS version 16
SPSS Inc., Chicago, Illinois). An intention to treat analysis was
used for calculating the effects of treatment on individuals in each
group.
The trial was registered with Current Controlled Trials Ltd
(www.controlled-trials.com) in accordance with the policy of the
International Committee of Medical Journal Editors [1] and was
assigned the unique identifier ISRCTN31894035. The protocol
for the trial can be accessed as a supplementary file Protocol S1 to
this publication.
Results
Forty-two patients were enrolled into the trial between 7th
December 2005 and 31st December 2007. The final assessment
and data entry was completed on 5th November 2008. The
RCT Methylprednisolone I in Type 1 Reactions
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participants flow through the study is illustrated in the CON-
SORT flow diagram (Figure 1).
Thirty-three males and nine females were recruited. Twenty-
two individuals were randomised to receive prednisolone only.
There were no statistically significant differences between the
groups with respect to gender, age, Ridley-Jopling classifica-
tion, or treatment with MDT (Table 1). The two groups did not
differ significantly in terms of the nature of the reaction, the
type of NFI at baseline or the pattern of old (. 6 months
duration) NFI.
Eight participants (19%) did not complete the full schedule of
follow-up. Five were randomised to the prednisolone arm and
three received MP. Efforts were made to get these individuals to
attend by telephoning or writing to them but without success. Two
of these individuals stopped attending whilst on corticosteroids.
Table 2 shows the number of individuals who experienced a
particular adverse event. Twenty-three participants experienced at
least one adverse event, twelve (54.5%) in the prednisolone arm
and 11 (55%) in the MP arm. Seven individuals experienced more
than one adverse event. There were no statistically significant
Figure 1. CONSORT flow diagram for the pilot study of individuals randomized to either intravenous methylprednisolone and oral
prednisolone or oral prednisolone alone.
doi:10.1371/journal.pntd.0001041.g001
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differences in the number of individuals experiencing a given
adverse event between the two groups of the study.
Two individuals (one from each arm of the study) experienced a
major adverse event. One was diagnosed with glaucoma and the
other with infected neuropathic ulcers. None of the participants
developed hypertension, tuberculosis or diabetes mellitus. The risk
ratio of having an adverse event (of any type; major or minor)
given that the participant received MP was 1.0083 (95% CI:
0.5817 to 1.7480; p = 0.9764) compared to prednisolone.
Individuals were most likely to experience an adverse event
whilst taking the first course of corticosteroids between days 1 and
112. Figure 2 is a Kaplan-Meier survival curve showing the
cumulative ‘‘survival’’ probability (i.e. not having an adverse event)
for individuals in each group. There was no significant difference
between the two groups (Log Rank (Mantel-Cox) 0.945).
Four individuals had their first adverse event after the initial
study intervention had been completed (post day 112). Two others
had a new adverse event after the intervention period. Two
individuals experienced an adverse event, weight gain and infected
neuropathic ulcers respectively, whilst not taking corticosteroids.
The total clinical severity scores, calculated using the validated
scale, for each arm of the study at day 1 (enrolment) and days 4,
29,113 and 337 are shown using boxplots (fig.3). There was a
downward trend in the total clinical severity scores of both groups.
There were no statistically significant differences between the
prednisolone and MP groups at any time point.
There was no significant difference in the median sensory scores
(corrected for impairment .6 months) of individuals in the two
groups at baseline. Both groups showed a downward trend in the
sensory scores during treatment but there were no significant
differences at any of the pre-specified time points. The Kaplan-
Meier survival analyses of deterioration in sensory score during the
study to days 29, 113 and 337 (fig.4) demonstrate that there is no
difference between the groups at day 29 but at day 113 there was a
significant difference in the probability of deterioration in
sensation between individuals in the two arms of the study
(p = 0.046). Patients in the prednisolone alone group were more
likely to experience deterioration in sensation between day 30 and
day 113. This effect is not maintained at the end of the study
follow-up period at day 337. The motor scores of the two groups at
Table 1. Baseline characteristics of study participants in each arm.
PREDNISOLONE (n=22) METHYLPREDNISOLONE (n=20)
Sex Female 5 4
Male 17 16
Median Age [years (Range; min-max)] Female 39 (19;35–54) 17.5 (25;17–42)
Male 40 (43;22–65) 28.5 (48;16–64)
Ridley-Jopling classification Tuberculoid 0 1
Borderline tuberculoid 11 12
Borderline borderline 0 3
Borderline lepromatous 10 3
Lepromatous leprosy 1 1
Reaction Type Skin Only 4 4
Skin and Nerves 8 13
Nerves Only 10 3
MDT Status Untreated 3 5
On treatment 14 10
Treated 5 5
doi:10.1371/journal.pntd.0001041.t001
Table 2. Minor and major adverse events.
Adverse Event Prednisolone Methylprednisolone chi square (Fisher’s exact)
Minor
Moon Face 2 6 0.123
Acne 5 5 1
Fungal infection 0 1 0.476
Gastric pain 5 2 0.414
NPP 2 2 1
Weight gain 1 0 1
Major Glaucoma 1 0 1
Infected ulcers 0 1 0.476
doi:10.1371/journal.pntd.0001041.t002
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baseline are not significantly different. They showed a downward
trend during the course of the study. There are no significant
differences between the scores of the group at any of the time
points. There were no significant differences between the groups in
the probability of an individual experiencing deterioration in
motor function at days 29, 113 or 337.
Figure 5 shows events when additional steroid was prescribed
and censoring individuals who were unavailable for further
assessment or who received prednisolone either inappropriately
or for ENL. There was no significant difference in the probability
of being prescribed additional prednisolone between the two
groups (Log Rank (Mantel Cox) p = 0.126). The amount of
additional prednisolone required by individuals randomised to
either treatment group did not differ significantly. The mean
amount of additional prednisolone prescribed during the study was
1252.5 mg (SD61862.0) for the MP group and 1432.7 mg
(SD61245.9) for the prednisolone alone group (p= 0.718).
Twenty individuals (47.6%) required additional prednisolone
because they experienced a deterioration of nerve function (n=11)
or a recurrence of a T1R (n=6) or both (n=3). Two individuals
received additional prednisolone inappropriately and two developed
ENL requiring prednisolone. Five of the 20 individuals (appropriately
prescribed additional prednisolone for a trial indication) required
prednisolone before day 112, the last day of the intervention period.
The median time to requiring additional prednisolone for these
individuals was 61 days (range=14–105) after enrolment when
individuals were receiving prednisolone 20 mg daily. The other 75%
had finished the prednisolone before experiencing a deterioration
requiring further treatment. The median number of days between
finishing the study intervention (day 112) and requiring additional
prednisolone was 63 days (range=2–224).
Analysing the additional corticosteroid requirement by Ridley-
Jopling classification fifty-two percent (12 of 23) of individuals with
borderline tuberculoid (BT) leprosy, 67% (two of three) of
individuals with borderline borderline (BB) leprosy, 38% (five of
13) of those with borderline lepromatous leprosy (LL) and 50%
(one of two) of lepromatous leprosy patients required additional
prednisolone for a trial indication (those with ENL were excluded).
Two of the BT patients had positive slit-skin smears. The median
time from enrolment to the deterioration requiring additional
prednisolone was 152 days for BT patients, 138 days for BB
patients, 125 days for BL patients and 313 days for those with LL.
There were no significant differences in the proportion of
individuals with a particular Ridley Jopling classification or the
time to requiring additional prednisolone.
Discussion
In this small, study the occurrence and timing of minor and
major adverse events did not differ significantly between the
prednisolone and the MP treated groups. The study was
underpowered and limited the ability to detect significant
differences of less than 30% between the groups. Twenty-one
(50%) individuals experienced at least one minor adverse event
and two (4.8%) a major adverse outcome. In the TRIPOD trials
8.4% (14/167) of the prednisolone treated Nepali cohorts
experienced a minor adverse event[16]. This was not significantly
different from the placebo treated group. The individuals in these
groups were treated with either 1.96 g or 2.52 g of prednisolone
depending on which of the three trials they were enrolled into.
The two major adverse events that occurred during the study
were glaucoma and infected neuropathic ulcers but these were
Figure 2. Time to first adverse event. (The vertical broken line is placed at day 113).
doi:10.1371/journal.pntd.0001041.g002
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probably not due to the trial medications. One individual
developed glaucoma at day 305. He developed ENL at day 111.
ENL like corticosteroid therapy is a recognised cause of secondary
glaucoma. He required continuous oral prednisolone (receiving a
total additional dose of 2.87 g of prednisolone between days 111
and 305) despite treatment of his ENL with high dose (300 mg
daily) clofazimine. The majority of individuals who develop ENL
require long term treatment and many become corticosteroid
dependent [19]. There were no cases of glaucoma in any of the
TRIPOD participants. Infected neuropathic ulcers affected one
individual treated with MP. This occurred 58 days after this man
completed the trial intervention. Two individuals in the TRIPOD
studies (one from the prednisolone treated group) developed
infected ulcers. It is not reported whether the prednisolone treated
person was taking the drug at the time the infection was diagnosed.
The symptoms of nocturia, polyuria and polydipsia were
reported by four (9.5%) of individuals. The two individuals who
had glycosuria did not complain of these symptoms. Their
glycosuria was not persistent and therefore not considered to be
clinically significant. The two individuals were both receiving
additional prednisolone at the time but neither had received MP.
There were no individuals in the study diagnosed with diabetes
mellitus. The TRIPOD 1 study reported one individual from the
prednisolone treated group who developed glycosuria. This was
considered a major adverse event in that study but the authors did
not comment whether this patient was diagnosed with diabetes
mellitus [20]. Three individuals in the steroid treated groups of the
three TRIPOD studies developed diabetes mellitus compared with
one in the placebo groups but this difference was not significant
[16].
The size of the study limited our ability to detect rare adverse
events however a much higher rate of acne and moon face was
recorded than the TRIPOD studies. Another factor that might
have reduced our estimation of adverse events is the duration of
follow-up which may have been too short, however most studies
have assumed that adverse events will occur during the treatment
phase predominantly. We were also unable to examine the effect
of our interventions on bone density which may be significantly
affected by corticosteroid therapy in the doses and durations
commonly used to manage leprosy T1R and NFI. The findings
would support the view that MP, in the doses used in the study, is
safe.
MP did not appear to have a larger therapeutic effect than
prednisolone alone on the symptoms and signs of leprosy T1Rs
and NFI in this study. The use of a validated scale to measure
leprosy T1Rs and NFI allows the comparison of the two groups in
this study. There were no significant differences in the total
severity score or the sensory or motor scores between the
prednisolone and MP treated groups at any of the pre-defined
time points. However there was a trend towards improvement in
Figure 3. Total severity score at days 1, 4, 29, 113, 337 (Circles denote individuals 1.5 times the interquartile range (IQR) outside the
box and asterisks denote individuals 3 times the IQR outside the box).
doi:10.1371/journal.pntd.0001041.g003
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sensory and motor scores during the study. Participants in the
prednisolone treated group were significantly more likely to have
experienced deterioration in sensory function than the MP treated
group by the end of the intervention (day 113). However this
difference was not sustained to the end of the study. This effect
may have occurred by chance as it was not reproduced in the skin
or in motor function. The number of participants contributing to
all of the survival analyses towards the end of the study is small and
the results therefore less reliable. This phenomenon of deteriora-
tion after stopping corticosteroids is similar to the results of the
TRIPOD 1 study of prednisolone given to patients as prophylaxis
to prevent the occurrence of reactions and NFI. It demonstrated a
protective effect of prednisolone compared with placebo during
the 16 weeks of treatment which was lost by 48 weeks. The higher
dose may have a greater effect whilst an individual is receiving
corticosteroids but not once they are no longer taking the drug.
Forty-five per cent of the MP group and 50% of the
prednisolone alone group were prescribed additional prednisolone.
Of the 20 individuals who required additional prednisolone 12
(60%) did not do so until at least 28 days after completing the trial
intervention. The clinical nature of the deterioration (skin or
nerves or both) did not differ significantly between those who
experienced it whilst receiving the study intervention and those
who experienced deterioration after completing it (x2 = 0.292).
The delay in deterioration in the majority of individuals requiring
additional prednisolone is similar to that seen in the TRIPOD 1
study[20].
After the start of this trial data suggesting that more prolonged
courses of prednisolone may be more effective in treating T1Rs
were published. The requirement for extra prednisolone was used
as the outcome measure in the multi-centre double blind
randomised controlled trial of three different prednisolone
regimens conducted in India [21]. The proportion of individuals
requiring additional prednisolone in the three groups was 24%,
31% and 46% respectively. Individuals who received prednisolone
for 20 weeks were significantly less likely to require additional
steroid than those treated for 12. However this does not necessarily
reflect clinical improvement. The decision to use additional
prednisolone was left to the individual clinician’s judgement at
each of the six centres. It is not clear how consistency was ensured
between individual physicians or at different stages of the trial.
The protocol of the MP study was stringent in treating NFI.
‘‘Mild’’ deterioration in NFI and NFI of short duration were both
treated. Any sustained (as little as one week) deterioration in
monofilament testing at even a single test site was an indication for
additional prednisolone and so a lower threshold for defining
deterioration is likely to have been employed in the current study.
This may in part account for the high proportion of individuals
who received additional prednisolone. It is likely that some of the
change labelled as deterioration was due to test response
variability. In the TRIPOD 2 cohort 27% of prednisolone treated
individuals with mild sensory impairment experienced deteriora-
tion necessitating additional prednisolone. A group with mild
isolated sensory impairment would be expected to require less
additional prednisolone than a group that included severe nerve
impairment both sensory and motor and marked skin involve-
ment.
The results of this small study should be interpreted with
caution but it would appear that given the available data MP does
not result in an increase in the number or severity of adverse
events in individuals with leprosy in Nepal. However close detailed
adverse event recording would still be required in any future
Figure 4. Time to deterioration of sensory function.
doi:10.1371/journal.pntd.0001041.g004
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studies of MP in this setting. The establishment of registries of
corticosteroid treated patients at specialised centres could facilitate
the collection of reliable adverse event data without the need to
resort to more costly randomised controlled trials.
The clinical outcome of patients in the two arms of this study
was not significantly different in terms of the validated clinical
severity scale. The MP treated group had significantly less
deterioration in sensory function during the 112 days of
corticosteroid therapy but this was not maintained to the end of
the 337 day follow-up period. This may be a reflection of the small
numbers in the study, particularly towards the end of follow-up. A
much larger study would be required to examine this potential
effect further. However given the high proportion of individuals
(who received MP) requiring additional prednisolone and the data
published by Rao and colleagues[21] we do not think further
clinical trials of high dose IV MP are warranted at present. Any
future studies must also take into account the greater cost of giving
intravenous treatment and its acceptability to patients.
This study has highlighted that corticosteroid treatment for
T1R and NFI is sub-optimal even when given in large doses for 16
weeks. The majority of patients who experienced a ‘‘re-reaction’’
required additional prednisolone after the 16 week corticosteroid
intervention had ended. It adds further support to the argument
that treatment should be given for longer durations. Investigating
risk factors for requiring additional prednisolone and the
differences between those who have deterioration in symptoms
whilst taking corticosteroids and those whose deterioration occurs
later (or not at all) might enable clinicians to identify those
individuals who might benefit from prolonged corticosteroid
treatment at the outset. At present there is convincing evidence
for corticosteroid regimes of at least 20 weeks [21] but some would
argue for 24 weeks [22] and others even longer [23]. The
development of more prolonged treatment protocols would
require further monitoring of adverse events and in particular
the long term sequelae of corticosteroid therapy. However studies
with adequate power using improvement in nerve function as the
primary outcome of the effect of corticosteroids and other agents
need to be conducted.
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